Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy-Reference-Cited by-同舟云学术

Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy

Published:2011-02-03 Issue:2 Volume:6 Page:e16664
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Castillo-Trivino Tamara,Mowry Ellen M.,Gajofatto Alberto,Chabas Dorothee,Crabtree-Hartman Elizabeth,Cree Bruce A.,Goodin Douglas S.,Green Ari J.,Okuda Darin T.,Pelletier Daniel,Zamvil Scott S.,Vittinghoff Eric,Waubant Emmanuelle

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference21 articles.

1. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.;RA Rudick;N Engl J Med,2006

2. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.;CH Polman;N Engl J Med,2006

3. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.;A Gajofatto;Mult Scler,2009

4. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis.;C Caon;Eur J Neurol,2006

5. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina.;A Carrá;Eur J Neurol,2008

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review];Neurology and Therapy;2023-10-11

2. Are highly active and aggressive multiple sclerosis the same entity?;Frontiers in Neurology;2023-03-03

3. Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?;Frontiers in Neurology;2022-04-15

4. Early Aggressive Treatment Approaches for Multiple Sclerosis;Current Treatment Options in Neurology;2021-05-15

5. Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing;Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques;2018-06-12